Tags

Type your tag names separated by a space and hit enter

Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension.
Am J Cardiovasc Drugs. 2009; 9(6):411-8.AJ

Abstract

Amlodipine/valsartan/hydrochlorothiazide (HCTZ) is a fixed-dose combination of the well established antihypertensive agents amlodipine (a calcium channel antagonist), valsartan (an angiotensin II receptor antagonist), and HCTZ (a thiazide diuretic). In patients with moderate or severe hypertension, triple combination therapy with amlodipine + valsartan + HCTZ produced significantly greater reductions from baseline in mean sitting systolic and diastolic BP (msSBP and msDBP) than either valsartan + HCTZ, amlodipine + HCTZ, or amlodipine + valsartan in a large, 8-week, randomized, double-blind, multinational, phase III trial. Furthermore, the proportion of patients achieving overall BP control at endpoint was significantly greater with the triple combination regimen than with any of the dual regimens, with significantly more triple combination recipients achieving msSBP and msDBP control at each assessment throughout the trial. Subgroup analyses of this study suggested that amlodipine + valsartan + HCTZ was generally more effective in reducing BP and providing overall BP control than the dual combination therapies, irrespective of age, race, gender, ethnicity, or hypertension severity. Several smaller studies provide data that support the efficacy of amlodipine + valsartan + HCTZ in patients whose BP is inadequately controlled with amlodipine + valsartan, amlodipine + HCTZ, or valsartan + HCTZ dual combination therapy. Treatment with amlodipine + valsartan + HCTZ for up to 8 weeks was generally well tolerated in the large, phase III trial, with most adverse events being transient and of mild to moderate severity.

Authors+Show Affiliations

Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19929039

Citation

Deeks, Emma D.. "Amlodipine/valsartan/hydrochlorothiazide: Fixed-dose Combination in Hypertension." American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions, vol. 9, no. 6, 2009, pp. 411-8.
Deeks ED. Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension. Am J Cardiovasc Drugs. 2009;9(6):411-8.
Deeks, E. D. (2009). Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension. American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions, 9(6), 411-8. https://doi.org/10.2165/11204350-000000000-00000
Deeks ED. Amlodipine/valsartan/hydrochlorothiazide: Fixed-dose Combination in Hypertension. Am J Cardiovasc Drugs. 2009;9(6):411-8. PubMed PMID: 19929039.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension. A1 - Deeks,Emma D, PY - 2009/11/26/entrez PY - 2009/11/26/pubmed PY - 2010/3/17/medline SP - 411 EP - 8 JF - American journal of cardiovascular drugs : drugs, devices, and other interventions JO - Am J Cardiovasc Drugs VL - 9 IS - 6 N2 - Amlodipine/valsartan/hydrochlorothiazide (HCTZ) is a fixed-dose combination of the well established antihypertensive agents amlodipine (a calcium channel antagonist), valsartan (an angiotensin II receptor antagonist), and HCTZ (a thiazide diuretic). In patients with moderate or severe hypertension, triple combination therapy with amlodipine + valsartan + HCTZ produced significantly greater reductions from baseline in mean sitting systolic and diastolic BP (msSBP and msDBP) than either valsartan + HCTZ, amlodipine + HCTZ, or amlodipine + valsartan in a large, 8-week, randomized, double-blind, multinational, phase III trial. Furthermore, the proportion of patients achieving overall BP control at endpoint was significantly greater with the triple combination regimen than with any of the dual regimens, with significantly more triple combination recipients achieving msSBP and msDBP control at each assessment throughout the trial. Subgroup analyses of this study suggested that amlodipine + valsartan + HCTZ was generally more effective in reducing BP and providing overall BP control than the dual combination therapies, irrespective of age, race, gender, ethnicity, or hypertension severity. Several smaller studies provide data that support the efficacy of amlodipine + valsartan + HCTZ in patients whose BP is inadequately controlled with amlodipine + valsartan, amlodipine + HCTZ, or valsartan + HCTZ dual combination therapy. Treatment with amlodipine + valsartan + HCTZ for up to 8 weeks was generally well tolerated in the large, phase III trial, with most adverse events being transient and of mild to moderate severity. SN - 1175-3277 UR - https://www.unboundmedicine.com/medline/citation/19929039/Amlodipine/valsartan/hydrochlorothiazide:_fixed_dose_combination_in_hypertension_ L2 - https://dx.doi.org/10.2165/11204350-000000000-00000 DB - PRIME DP - Unbound Medicine ER -